Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Double-blind, Randomized, Placebo-controlled Extension Study Assessing the Efficacy and Long-term Safety of a 2 mg Dose of TH9507, a GHRH Analog, in HIV Subjects With Excess Abdominal Fat Accumulation

Next Previous
Trial Profile

A Multicenter, Double-blind, Randomized, Placebo-controlled Extension Study Assessing the Efficacy and Long-term Safety of a 2 mg Dose of TH9507, a GHRH Analog, in HIV Subjects With Excess Abdominal Fat Accumulation

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tesamorelin (Primary)
  • Indications HIV-associated lipodystrophy syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors Theratechnologies

    • Most Recent Events

    • 22 Feb 2023 Results (n=400) assessing whether treatment with tesamorelin was associated with changes in Metabolic Syndrome classification from 2 Phase III trials of tesamorelin, presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023.
    • 22 Feb 2023 Results presented in the Thera Technologies media release.
    • 22 Feb 2023 According to Thera Technologies media release, the company presented a data suggesting that tesamorelin may improve metabolic profiles in people with HIV (PWHIV) by reducing excess visceral abdominal fat (EVAF) at the 30th Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, Washington.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top